Bimatoprost, a novel efficacious ocular hypotensive drug now recognized as a member of a new class of agents called prostamides

Drug Development Research

Volumn 68, Issue 4, 2007, Pages 147-155

  Burk, Robert M ^a   Woodward, David F ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; 11 PIVALOYLPROSTAGLANDIN F2 ALPHA; 11,15 DIPIVALOYLPROSTAGLANDIN F2 ALPHA; AGN 190910; AGN 190911; AGN 190988; AGN 191045; AGN 191129; AGN 204396; AGN 211334; BIMATOPROST; LATANOPROST; PROSTAGLANDIN F2 ALPHA; PROSTAMIDE; PROSTANOID; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; AQUEOUS HUMOR FLOW; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SPHINCTER PUPILLAE MUSCLE;

EID: 36049014081     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20176     Document Type: Review

References (48)

1. 2α alpha and its isopropyl ester on normal and glaucomatous human eyes. Prog Clin Biol Res 312:447-458.
2. 2α-1-isopropyl ester. Exp Eye Res 44:217-226.
3. Bito LZ, Draga A, Blanco J, Camras CB. 1983. Long-term maintenance of reduced intraocular pressure by daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci 24:312-319.
4. 2α) analogues with neutral substituents at position 1 is predicted by the isolated cat iris sphincter smooth muscle preparation but not Ca2+ signaling in Swiss 3T3 cells. In: Honn KV, Marnett LJ, Nigram S, Serhan CN, Dennis EA. (editors). Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Vol 5. Kluwer Academic/Plenum. p 327-330.
5. 2α alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucomatous patients. Ophthalmol 96:1329-1336.
6. Chen J, Senior J, Marshall K, Abbas F, Dinh H, Dinh T, Wheeler LA, Woodward DF. 2005. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br J Pharmacol 144:493-501.
7. 2α. Br J Ophthalmol 78:560-567.
8. Christiansen GA, Nau CB, McLaren JW, Johnson DH. 2004. Mechanism of ocular hypotensive action of bimatoprost (lumigan) in patients with ocular hypertension or glaucoma. Ophthalmol 111:1658-1662.
9. Davies SS, Ju W-K, Neufeld AH, Abran D, Chemtob S, Roberts LJ. 2003. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocular Pharmacol Ther 19:45-54.
10. Dubiner H, Cooke D, Dirks M, Stewart W, Vandenburgh AM, Felix C. 2001. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30 day comparison with latanoprost. Surv Ophthalmol 45:S353-S360.
11. Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, Leske MC, Mitchell P, Congdon N, Kempen J. 2004. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 122:532-538.
12. 2α in the human eye. Graefes Arch Clin Exp Ophthalmol 222:139-141.
13. 2+ sensitivity of the pig iris sphincter muscle. Invest Ophthalmol Vis Sci 47:4865-4871.
14. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, Vandenburgh A, Chen K, Whitcup SM. 2002. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 120:1286-1293.
15. Kozak KR, Crews BC, Morrow JD, Wang L-H, Ma YH, Weinander R, Jakobsson P-J, Marnett LJ. 2001. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol ester and ethanolamides. J Biol Chem 277:44877-44885.
16. Krauss AH-P, Woodward DF. 2004. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol 49:S5-S11.
17. 2 agonist) on Cyr 61 and CTGF gene expression. J Biol Chem 278:27267-27277.
18. Maddox YT, Ramwell PW, Shiner CS, Corey EJ. 1978. Amide and 1-amino derivatives of prostaglandins as prostaglandin antagonists. Nature 273:549-552.
19. Matias I, Chen J, De Petrocellis L, Bisogno T, Ligresti A, Fezza F, Krauss AH-P Shi L, Protzman CE, Li C, Liang Y, Nieves AL, Kedzie KM, Burk RM, Di Marzo V, Woodward DF. 2004. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309:745-757.
20. Maxey KM, Johnson JL, Labreque J. 2002. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 47:S34-S40.
21. Nelson NA, Jackson RW, Au AT. 1975. Synthesis and biological activity of 2-decarboxy-2-(tetrazol-5-yl) prostaglandins. Prostaglandins 10:303-306.
22. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. 2003. A six-month randomized clinical trail comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135:55-63.
23. Parrish RK, Palmberg P, Sheu W-P, XLT Study Group. 2003. A comparison of latanoprost, bimatoprost, and travaprost in patients with elevated intraocular pressure: a 12-week randomized, masked evaluation multicenter study. Am J Ophthalmol 135:688-703.
24. Quigley HA, Broman AT. 2006. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:262-267.
25. Resul B, Stjernschantz J, No K, Liljebris C, Selen G, Astin M, Karlsson M, Bito LZ. 1993. Phenyl-substituted prostaglandins: potent and selective antiglaucoma: agents.
26. Resul B, Stjernschantz J, Selen G, Bito L. 1997. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 41:S47-S52.
27. Schaaf TK, Hess H-J. 1979. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogs. J Med Chem 22:1340-1346.
28. Selen G, Stjernschantz J, Resul B. 1997. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 41:S125-S128.
29. Sharif N, Crider JY, Davis TL. 2000. AL-3138 antagonizes FP prostanoid receptor-mediated inositol phosphates generation: comparison with some purported FP antagonists. J Pharm Pharmacol 52:1529-1539.
30. Sharif NA, Williams GW, Kelly CR. 2001. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol 432:211-213.
31. Sharif NA, Kelly CR, Crider JY. 2002. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocular Pharmacol Ther 18:313-324.
32. 2+ mobilization studies. Prostaglandins Leukot Essent Fatty Acids 68:27-33.
33. Sjoquist B, Tajallaei S, Stjernschantz J. 1999. Pharmacokinetics of latanoprost in the cynomolgus monkey. First communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung 49:225-233.
34. 2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res 80:135-145.
35. Stjernschantz J, Resul B. 1992. Phenyl substituted prostaglandin analogs for glaucoma. Drugs Future 17:691-704.
36. Wan Z, Woodward DF, Cornell C, Fliri H, Martos J, Pettit S, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk K, Strubel CS, Stamer WD. 2007. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol 48:4107-4115.
37. 2+ signals in Swiss 3T3 cells. Biochem Pharmacol 47:1567-1574.
38. 2α (FP) receptor stimulation. Invest Ophthalmol Vis Sci 30:1838-1842.
39. 2α ester prodrugs and receptor selective prostaglandin analogs. J Ocul Pharmacol 10:177-193.
40. Woodward DF, Andrews SW, Burk RM, Garst ME. 1994b. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents. US Patent 5,352,708
41. Woodward DF, Fairbairn CE, Krauss AH, Lawrence RA, Protzman CE. 1995. Radioligand binding analysis of receptor subtypes in two FP receptor preparations that exhibit different functional rank orders of potency in response to prostaglandins. J Pharmacol Exp Ther 273:285-287.
42. 2α prodrugs in ocular tissue. Exp Eye Res 63:411-423.
43. 2α with a hydroxyl or methoxy substituents provides biologically unique compounds. Br J Pharm 130:1933-1943.
44. Woodward DF, Krauss AH-P, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD-S, Garst ME, Brar B, Wheeler LA, Kaplan LJ. 2001. The pharmacology of bimatoprost (Lumigan®). Surv Ophthalmol 45:S337-S345.
45. Woodward DF, Krauss AH-P, Chen J, Liang Y, Li C, Protzman CE, Bogardus A, Chen R, Kedzie KM, Krauss HA, Gil DW, Kharlamb A, Wheeler LA, Babusis D, Welty D, Tang-Liu DD-S, Cherukury M, Andrews SW, Burk RM, Garst ME. 2003. Pharmacological characterizations of a novel antiglaucoma agent, bimatoprost (AGN 192024). J Pharmacol Exp Thor 305:772-785.
46. Woodward DF, Phelps RL, Krauss AH-P, Weber A, Short B, Chen J, Liang Y, Wheeler LA. 2004. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev 22:103-120.
47. Woodward DF, Krauss AH, Wang JW, Protzman CE, Nieves AL, Liang Y, Donde Y, Burk RM, Landsverk K, Struble C. 2007. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin ethanolamides) in the feline iris. Br J Pharmacol 150:342-352.
48. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272:21181-21186.